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     Mesoderm is one of the three germ layers 
produced during gastrulation from which 
muscle, bones, kidneys and the cardiovascular 
system originate. Understanding the 
mechanisms controlling mesoderm specification 
could be essential for a diversity of applications, 
including the development of regenerative 
medicine therapies against diseases affecting 
these tissues. Here, we use human pluripotent 
stem cells (hPSCs) to investigate the role of cell 
cycle in mesoderm formation. For that, proteins 
controlling G1 and G2/M cell cycle phases were 
inhibited during differentiation of hPSCs into 
lateral plate, cardiac and presomitic mesoderm 
using small molecules or by conditional knock 
down. These loss of function experiments 
revealed that CDKs and pRb phosphorylation 
are necessary for efficient mesoderm formation 
in a context-dependent manner. Further 
investigations showed that inhibition of the 
G2/M regulator CDK1 decreases BMP signaling 
activity specifically during lateral plate 
mesoderm formation while reducing 
FGF/ERK1/2 activity in all mesoderm subtypes. 
Taken together, our findings reveal that cell 
cycle regulators direct mesoderm formation by 
controlling the activity of key developmental 
pathways.       
 
      
      Gastrulation represents an essential stage of 
early development when the three primary germ 
layers endoderm, mesoderm and ectoderm are 
formed. Of particular interest for the current study, 
mesoderm specification occurs through a 
mesendoderm progenitor which is shared with 
endoderm. Mesoderm is then patterned in different 
subpopulations depending of their anteroposterior 
location in the primitive streak where a gradient of 
Nodal and BMP signaling and interplay with WNT 
and FGF leads to the formation of different cell 
types (1–3). At the very posterior end of the 
primitive streak, high BMP4 and low Nodal pattern 
extraembryonic mesoderm and the blood lineage, 
followed by anterior lateral plate mesoderm (1, 4, 
5). The lateral plate mesoderm lineage gives rise to 
cardiovascular cell types such as smooth muscle 
cells and endothelial cells. At the more anterior part 
moderate levels of Nodal and BMP4 pattern cardiac 
mesoderm, which gives rise to cardiomyocytes, the 
main cell type constituting the heart (4, 6). In the 
middle anterior primitive streak, paraxial 




(presomitic) mesoderm is formed (7) which gives 
rise to bone, cartilage and skeletal muscle and 
requires WNT signaling. Understanding the 
mechanisms directing the specification of these 
different types of mesoderm could have a broad 
implication for developmental biology but also in 
the context of diseases affecting stem cell 
differentiation. Nonetheless, studying these 
mechanisms at the molecular level remains 
challenging in vivo due to technical and ethical 
limitations in human. 
      Human pluripotent stem cells (hPSCs) provide 
a powerful alternative since they can proliferate 
almost indefinitely while maintaining the capacity 
to differentiate efficiently into the three germ layers 
(8). Thus, hPSCs have been used to uncover 
mechanisms directing germ layer specification (9–
11). Of particular interest, studies have shown key 
functions for the cell cycle machinery in the 
specification of endoderm versus ectoderm and 
exist from the pluripotent state. Indeed,  G1 and 
G2/M transition regulators have been shown to play 
a key role in pluripotency maintenance and cell fate 
decisions of hPSCs by controlling transcription 
factors, signaling pathways and epigenetic 
regulators (12–16). More precisely, knockdown of 
CDK2 results in cell cycle arrest, decreased 
expression of pluripotency markers and 
differentiation towards extraembryonic lineages 
(17). Similarly, abrogation of cyclin D1/2/3 results 
in loss of pluripotency and differentiation towards 
the mesendoderm lineage (13) indicating a direct 
role of cyclins and CDKs in the maintenance of 
pluripotency and cell identity. Furthermore, siRNA 
mediated knockdown of CDK1 results in changes 
in cell morphology, decrease in pluripotency 
marker expression, accumulation of DNA damage 
and mitotic deficiencies (18).  
      At the epigenetic level, histone modification 
H3K4me3 has been shown to be more abundant on 
developmental genes in the G1 phase of the cell 
cycle. Interestingly, the histone methyltransferase 
catalysing this modification called MLL2, was also 
shown to be higher in the late G1 phase and 
enriched on promoters of the cell cycle regulated 
genes SOX17 and GATA6. The recruitment of 
MLL2 on these developmental genes was shown to 
be mediated by phosphorylation of MLL2 by 
CDK2, establishing a role of cell cycle regulators in 
regulating epigenetic processes in hESCs (15). 
      Moreover, the cell cycle machinery and 
specifically the cyclin D-CDK4/6 complex has a 
vital role in guiding endoderm formation through 
regulation of the Nodal/Activin signaling pathway 
effector Smad2/3. Cyclin D also acts as a 
transcriptional regulator independently of its role in 
the cell cycle and signaling regulation. ChIP-
sequencing analyses have shown that cyclin D 
binds to and recruits transcriptional corepressor and 
coactivator complexes onto developmental gene 
loci, thus regulating their transcription and 
ultimately cell fate decisions (14).  
      Most of these studies, if not all, have been 
performed in the context of pluripotency while the 
role of the cell cycle in guiding differentiation 
especially mesoderm specification is elusive. Here, 
we decided to address this question by taking 
advantage of protocols allowing differentiation of 
hPSCs into different mesoderm subtypes including 
lateral plate mesoderm (LPM), cardiac mesoderm 
(CM) and presomitic mesoderm (PSM) (19, 20). 
The corresponding culture system was used to 
investigate the role of G1 and G2/M cell cycle 
regulators in guiding mesoderm specification, 
especially the role of the cell cycle machinery in 
regulation of key developmental signaling 
pathways such as BMP, WNT and FGF. Inhibition 
of both G1 and G2/M cell cycle regulators by small 
molecules blocked mesoderm subtype formation 
with different efficacy and in a context-dependent 
manner. Additional analyses into the molecular 
mechanisms responsible for this phenotype, 
revealed that inhibition of the G2/M regulator 
CDK1 decreased BMP activity during LPM 
formation while reducing FGF/ERK activity in all 
mesoderm subtypes studied, thereby blocking 
differentiation. Our results demonstrate that cell 
cycle regulators are essential for the early stage of 
mesoderm formation and that this function is 
achieved through regulation of key developmental 
signalling pathways such as FGF/ERK. This 
knowledge will help to improve protocols for 
generating mesoderm cells in vitro and could also 
be relevant for the development of new therapies 
promoting tissue regeneration. 
 
RESULTS 
      Characterisation of mesoderm subtypes 
generated from hPSCs – In this study, we took 
advantage of established protocols for 




differentiating hPSCs into different mesoderm 
subtypes. Specifically, we took advantage of 
chemically defined culture conditions to drive 
differentiation of hPSCs into cardiac (CM), lateral 
plate (LPM) and presomitic (PM) mesoderm.  
These methods rely on growth factors known to 
direct mesoderm specification in vivo (20–22). As a 
result, hPSCs differentiation follows a natural path 
of development including the production of cells 
closely resembling cells arising along the antero-
posterior axis of the primitive streak during 
development. In sum, hPSCs were induced to 
generate LPM, CM and PSM mesoderm for 36 
hours followed by the addition of another cocktail 
of growth factors and small molecules to generate 
functional cell types such as smooth muscle cells, 
cardiomyocytes and chondrocytes (Fig. 1A) (20, 22, 
23). During induction of all mesoderm subtypes, we 
observed a decrease in pluripotency marker 
expression such as NANOG and upregulation of 
pan-mesoderm marker BRACHYURY (or T) (Fig. 
1B-G). LPM induction was confirmed by the 
increase in NKX2.5 expression at day 5 (Fig. 1B, C) 
and further differentiation toward smooth muscle 
cells was validated by the expression of calponin 
(CNN1) and transgelin (TAGLN) at day 17 (Fig. 1B, 
C). During CM induction we observed expression 
of EOMES at day 1.5. CM identity was confirmed 
by the high expression of NKX2.5 at day 6 while 
further differentiation resulting in beating 
cardiomyocytes expressed the genes ACTN2 
(coding for the microfilament protein α-Actinin) 
and TNNT2 (coding for cardiac Troponin T) (Fig. 
1D, E). Finally, PSM induction was associated with 
CDX2 expression at day 1.5 followed by 
chondrocyte differentiation as shown by the 
expression of the cartilage matrix proteins collagen 
2a (or COL2A1) and aggrecan (ACAN) (Fig. 1F, G). 
Immunostaining analyses showed PAX3 
expression in PSM while alcian blue staining 
confirmed production of proteoglycans such as 
aggrecan by terminally differentiated chondrocytes 
(Fig. 1G). Taken together, these results reinforce 
previous results by showing the robustness of our 
protocols to drive differentiation of hPSCs into 
different types of mesodermal progenitors.  
 
      Inhibition of G1 and G2/M cell cycle regulators 
blocks induction of mesoderm subtypes in a 
context-dependent manner – To explore the 
importance of cycle machinery in mesoderm 
specification, we next investigated the effect of the 
inhibition of G1 and G2/M regulators on 
differentiation. For that, we used small molecule 
inhibitors for CDK4/6 (PD-0332991), CDK2 
(roscovitine), phosphorylation of retinoblastoma 
protein (RRD-251) and CDK1 (RO-3306 (Fig. 2A). 
Of note, these small molecules are commonly used 
to study the function of cell cycle regulators in a 
diversity of systems. hESCs were induced to 
differentiate into the three mesoderm subtypes 
LPM, CM and PSM in the presence of the cell cycle 
regulators inhibitors for 36 hours and the resulting 
cells were harvested for gene expression and 
immunocytochemistry analyses (Fig. 2B). The cell 
cycle inhibitors did not cause cell death or 
cytotoxicity as morphology and cell density was not 
majorly affected (Fig. S1A). In the presence of the 
CDK1 inhibitor, slightly more cell death was 
observed as compared to the rest of the conditions 
tested (Fig. S1A). To exclude the possibility that 
any effects on the differentiation are due to 
cytotoxicity of the small molecule cell cycle 
inhibitors, we assessed cell death after induction of 
the 3 mesoderm subtypes using Annexin V and 
propidium iodide analysis. Overall, no big 
differences were observed in the percentage of dead 
cells after treatment with the small molecule cell 
cycle inhibitors as compared to DMSO-treated and 
pluripotent cells. The slightly higher percentage of 
dead cells observed upon CDK1 inhibitor treatment 
during CM and PSM induction is in agreement to 
the morphology and density observed in the culture 
(Fig. S1B-G). 
      Concerning LPM differentiation, ppRb and 
CDK1 inhibition were associated with strong 
downregulation of T expression (Fig. 2C). 
Moreover, the posterior primitive streak marker 
HAND1 was also downregulated upon inhibition of 
all regulators, with the strongest effect being 
observed during inhibition of CDK4/6 and CDK1 
(Fig. 2C). The inefficient formation of mesoderm 
expression of the master regulator T was also 
validated at the protein level where a reduction in 
expression of BRACHYURY was observed upon 
CDK4/6 and CDK2 inhibition whereas inhibition of 
ppRb and CDK1 resulted to complete loss of 
BRACHYURY expression (Fig. 2D). Of note, 
downregulation of the pluripotency markers OCT4 
and NANOG was not stopped suggesting that 
inhibition of cell cycle regulators did not block 
differentiation of hPSCs (Fig. S2A). Interestingly, 




inhibition of CDK2 and ppRb caused more 
effective downregulation of OCT4 and NANOG 
suggesting further regulation of not only 
differentiation marker, but also pluripotency 
marker expression. 
      Similarly, CM specification was strongly 
altered upon inhibition of all cell cycle regulators, 
as shown by the reduction in T and EOMES 
expression (Fig. 2E, F). Interestingly, inhibition of 
CDK2, ppRb and CDK1 resulted in maintenance of 
OCT4 and NANOG expression during the 
differentiation process (Fig. S2B). Thus cell cycle 
regulators may be necessary to exit pluripotency 
during differentiation of specific types of 
mesoderm. While no significant differences were 
observed in pluripotency markers, there was 
slightly higher expression of OCT4 and NANOG 
during inhibition of CDK2, ppRb and CDK1.  
      PSM induction was also inefficient upon 
inhibition of the cell cycle regulators. Expression of 
T was more significantly reduced upon inhibition of 
CDK2 ppRb and CDK1 and expression of CDX2 
upon inhibition of CDK4/6, CDK2 and CDK1 (Fig. 
2G). Immunostaining analysis for BRACHYURY 
expression confirmed RT-qPCR results (Fig. 2H). 
Expression of pluripotency genes did not 
significantly differ between DMSO and inhibitor-
treated cells with the exception of CDK1 inhibition 
which led to the maintenance of OCT4 and NANOG 
expression during the differentiation process (Fig. 
S2C). This suggests that CDK1 could be necessary 
for the downregulation of these genes and exit from 
pluripotency during PSM formation.  
      Taken together, these results show that cell 
cycle regulators are essential for mesoderm 
formation and subtype specification. Of note, the 
strong effect seen on T expression suggests that 
these regulators may be involved during the early 
stage of mesoderm specification corresponding to 
primitive streak formation. Furthermore, CDKs and 
the pRb protein could also be necessary for the fine-
tuning of pluripotency marker expression 
depending on the mesoderm subtype generated as 
suggested by the pattern of expression for OCT4 
and NANOG. 
      Inhibition of G1 phase regulators does not 
significantly affect the activity of BMP, WNT and 
FGF signaling pathways – Based on our previous 
results showing that CDK4/6 could control the 
activity of Activin/Nodal signaling (13), we 
hypothesised that regulators of G1 phase including 
CDK4/6, CDK2 and pRb could control signaling 
pathways such as BMP, WNT, and FGF which are 
known to direct mesoderm specification. To 
confirm this possibility, we studied the effect of G1 
CDK inhibitors on the activity of these signaling 
pathways during the specification of different types 
of mesoderm. Effect on BMP signaling was 
analysed in the context of LPM and CM formation 
since BMP4 is used drive formation of these 
mesoderm subtypes while effect on WNT signaling 
was analysed during PSM formation since 
CHIR99021, a WNT agonist, is driving this 
mesoderm formation. Finally, effect on FGF 
signaling was primarily analysed in pluripotent 
cells to avoid interference with other pathways. 
Indeed, FGF2 is important for all three mesoderm 
subtypes LPM, CM and PSM and thus it was more 
informative to test the corresponding inhibitors in 
pluripotency conditions before further 
investigations during differentiation. Each 
mesoderm subtype was induced in the presence of 
the inhibitors for 36 hours with the exception of 
FGF signaling, for which hESCs were grown for 12 
hours in the presence of inhibitors. Prior to 
harvesting for Western blot analysis, cells were 
freshly fed with media supplemented with the 
inhibitors. and subsequently harvested for Western 
blot analyses (Fig. 3A).  
      Despite several analyses and different 
conditions of treatment, inhibition of cell cycle 
regulators in these different culture conditions did 
not affect the levels of phospho-SMAD1/5 (Fig. 
3B-C) while minor differences were observed in the 
levels of phospho-β-catenin (Fig. 3D). Among the 
different conditions tested. A slight increase in the 
levels of phospho-β-catenin was observed upon 
treatment with the CDK4/6 and ppRb inhibitors, 
suggesting that increased degradation of β-catenin 
can lead to lower WNT signaling, contributing to 
the downregulation of T observed during PSM. 
Similarly to phospho-SMAD1/5, the level of 
phospho-ERK1/2 did not show major changes upon 
treatment with the small molecule inhibitors (Fig. 
3E). Thus, G1 phase regulators appear to have only 
mild effects on BMP, WNT and FGF signaling, and 
the pathways appear to be mostly active in the 
presence of the inhibitors, suggesting that the 
regulation of mesoderm formation by G1 regulators 
occurs through alternative mechanisms.  
 




      Inhibition of CDK1 decreases the activity of 
BMP and FGF signaling pathways – We next 
investigated the effect of CDK1 inhibition on the 
same signaling pathways using similar conditions. 
Interestingly, CDK1 inhibitor strongly reduced the 
total level of SMAD1 resulting to a dramatic 
decrease in the levels of available phospho-
SMAD1/5 (Fig. 4A) specifically during LPM 
differentiation but not induction of CM (Fig. 4B). 
Thus, CDK1 could control BMP signaling only in 
certain mesoderm subtypes. Further 
characterisation showed that WNT signaling 
pathway was not affected by CDK1 (Fig. 4C) while 
FGF/ERK1/2 signaling pathway was severely 
down regulated upon inhibition of CDK1 in 
pluripotency conditions (Fig. 4D) and even more 
strongly in all mesoderm subtypes. The most severe 
phenotype was observed in LPM and CM induction 
where loss of phospho-ERK1/2 was almost 
complete (Fig. 4, E and F) while this reduction was 
less severe in PSM (Fig. 5G).      To confirm these 
results, we decided to genetically validate this 
phenotype by knocking-down CDK1 in hESCs. For 
that, we took advantage of the single-step optimized 
inducible knockdown (sOPTiKD) platform as 
previously described (24). The resulting CDK1 
iKD-hESCs were treated with tetracycline for 5 
days to induce the knockdown of CDK1 and 
subsequently differentiated into the three 
mesoderm subtypes in the presence of tetracycline. 
Western blot analysis confirmed the efficient 
knockdown of CDK1 with 80%, 60% and 90% 
decrease in expression in LPM, CM and PSM 
respectively (Fig. 4H, first panel). Western Blot 
analyses showed that decrease in CDK1 expression 
was associated with reduced ERK1/2 
phosphorylation (Fig. 4H, second panel). The 
strongest effect was observed in LPM and CM 
induction whereas reduction in PSM was less 
severe, recapitulating the phenotype obtained by 
inhibiting CDK1 with small molecule. Taken 
together, these results demonstrate that CDK1 is 
necessary for the activity of BMP and FGF 
signaling during mesoderm specification.  
 
      Inhibition of FGF/ERK1/2 signaling blocks 
induction of all mesoderm subtypes – our results 
also imply that ERK1/2 should be essential for 
mesoderm differentiation. To validate this 
hypothesis, we induced mesoderm subtype 
formation for 36 hours in the presence of the 
ERK/MEK1/2 inhibitor PD0325901. Strikingly, 
presence of this small molecule resulted in the 
complete loss of expression of T during LPM (Fig. 
4I) and PSM induction (Fig. 4K) and loss of 
EOMES during CM induction (Fig. 4J). Taken 
together, these results demonstrate that mesoderm 
subtype induction is controlled by the interplays 
between CDK1 and FGF/ERK1/2 which are 
necessary for the induction of key mesoderm 
markers but also the down regulation of 
pluripotency factors.  
 
DISCUSSION 
      In this study, we investigated the role of G1 and 
G2/M cell cycle regulators in the specification of 
mesoderm subtypes. We used pharmacological 
inhibition of CDK4/6, CDK2 and CDK1 using the 
small inhibitors PD-0332991, roscovitine and RO-
3306 respectively. Additionally, retinoblastoma 
protein (pRb) was maintained in its active state by 
inhibiting its phosphorylation with the small 
molecule RRD-251. Inhibition each cell cycle 
regulator disrupted specific mesoderm 
differentiation. CDK4/6 appears to be necessary for 
expression of T in all the mesoderm subtypes even 
though more significant changes were observed 
during ppRb and CDK1 inhibition. Interestingly, it 
was previously shown that CDK4/6 inhibits 
endoderm formation by blocking the nuclear import 
of SMAD2/3 (13). Thus, cell cycle regulators could 
be germ layer specific and context- dependent. In 
our mesoderm differentiation model, only anterior 
primitive-like and subsequent cardiac mesoderm is 
induced in the presence of Activin and high activity 
of SMAD2/3 is likely to perturb mesoderm 
induction. Thus, CDK4/6 could be necessary to safe 
guard mesoderm induction against ectopic Activin 
signaling activity.  
      Interestingly, CDK2 and phosphorylation of 
pRb also appear to be necessary for mesoderm 
specification. CDK2 is known to control 
phosphorylation of pRb during cell cycle 
progression and thus both regulators could interact 
during differentiation  (Reviewed in Harbour and 
Dean, 2000). Accordingly, the most important 
effect of their inhibition is the loss of T expression 
specifically during LPM induction. These results 
also suggest that CDK2 and/or pRb could control 
the early stage of mesoderm induction 
corresponding to the primitive streak formation in 




vivo.  Despite their functional importance, we were 
not able to establish a link between G1 phase 
regulators with signaling pathways controlling 
differentiation. Thus, CDK2/pRb could control 
alternative mechanisms necessary for mesoderm 
patterning. It has been previously proposed that cell 
cycle regulators and specifically CDK2 regulates 
epigenetic modifiers such as the MLL 
methyltransferase and guides it to developmental 
genes in the late G1 phase (15). This observation 
could also apply in our system and specifically it 
would be of interest to identify whether MLL2 is 
phosphorylated by CDK2 or CDK4/6 during 
mesoderm differentiation and whether there is 
recruitment of MLL2 to genes guiding mesoderm 
specification such as BRACHYURY whose 
expression has been shown to rely on-MLL2 (15). 
      In contrast to G1 cell cycle regulators, we 
observed a strong reduction in FGF/ERK1/2 
signaling upon CDK1 inhibition in all mesoderm 
subtypes, and a reduction in BMP4/SMAD1/5 
signaling in during LPM induction. This 
observation is consistent with the interplay of FGF 
and BMP4 signaling in hESCs which is known to 
be key for mesoderm differentiation (26, 27). Thus, 
CDK1 could be a link between the two signaling 
pathways, whose coordinated function is necessary 
for the expression of key mesoderm inducers such 
as T. FGF has been shown to regulate T expression 
in xenopus, zebrafish, chick and mouse embryos 
(28–33) and a correlation of FGF signaling and T 
expression was reported in human cancer cell lines 
(34). Thus, our results support in vivo and in vitro 
findings and suggest that a similar mechanism may 
be conserved in human stem cells.  
      Beyond differentiation markers, we also 
observed that inhibition of CDK2, ppRb and CDK1 
could affect pluripotency markers. Decrease in 
OCT4 and NANOG expression was aggravated 
during LPM induction upon inhibition of CDK2 
and ppRb and inhibited during PSM induction upon 
inhibition of CDK1. Thus, for some mesoderm 
subtypes, cell cycle regulators could fine-tune exit 
from pluripotency mechanisms in agreement with 
previous reports (12), while for other mesoderm 
subtypes they could regulate the expression of 
pluripotency factors, guiding differentiation (20, 
35–37).  
      Our results, suggest an interesting link between 
pluripotency factor expression and upregulation of 
differentiation genes. It has been shown that during 
BMP-induced differentiation, NANOG expression 
is prolonged (through ERK signaling) and NANOG 
knockdown causes loss of T expression in hESCs 
(26). Additionally, functional studies showed that 
loss of NANOG reduces expression of basal levels 
of primitive streak genes and loss of OCT4 results 
in T decrease in hESCs. Conversely, 
overexpression of NANOG was shown to increase 
levels of primitive streak genes (35). Moreover, a 
recent study has identified that ERK2 and CDK1 
both phosphorylate NANOG (38). This is an 
intriguing correlation suggesting that the two 
kinases could regulate NANOG stability through 
phosphorylation in the G2/M phase in a cooperative 
manner to prevent overexpression or excessive 
decrease during the differentiation process. 
Considered together, these reports reinforce the 
data presented in the current study.  
      Importantly, validations of our finding in vivo 
remain challenging. Indeed, knockout of G1 cell 
cycle regulators results in viable embryos (39–43) 
while only the simultaneous knockout of CDK2 and 
CDK4 is embryonic lethal (44). These results 
suggest that G1 CDKs are not essential for embryo 
development at the early stages, possibly due to 
functional redundancy often witnessed among these 
regulators. On the other hand, knockout of CDK1 is 
essential for cell proliferation during early 
development and its absence causes embryonic 
lethality at E10.5 (45). CDK1 thus is considered a 
master regulator of cell cycle transition. 
Interestingly, the essential role of CDK1 has been 
further corroborated as it was shown to compensate 
for loss of CDK2, CDK4 and CDK6 in the cells by 
binding to cyclins E, A, B and D (46, 47), 
highlighting its essential role throughout 
development.  
      Of note, inhibition of CDK1 in our system 
during the differentiation process could be blocking 
cell cycle progression, thus contributing to the 
inefficient differentiation of the cells. While this 
being a possibility, studies from our lab have shown 
that blocking or slowing down cell cycle during 
differentiation using small molecules such as 
nocodazole does not prevent the induction of 
specific markers such as T (Grandy RA., et al., 
unpublished). 
      Importantly, we cannot exclude that CDK1 
could control additional molecular mechanisms 
directing differentiation. Indeed, CDK1 is also 
known to control epigenetic modifiers such as the 




polycomb group protein enhancer of zeste 
homologue 2 (EZH2). This protein is a histone 
methyltransferase and catalyses H3K27me3 
leading to gene silencing and has been shown to 
have a role in maintenance of pluripotency in PSCs, 
amongst its multiple other roles (48–50). 
Intriguingly, CDK1 was shown to control EZH2 
activity through phosphorylation (51) while EZH2 
inhibition was shown to be important for mesoderm 
formation in hESCs (52). Considered together, 
these previous studies suggest that CDK1 could 
coordinate epigenetic modification with signaling 
pathway activity during progression of mesoderm 
differentiation.  
      Taken together, our results show that cell cycle 
regulators are essential for mesoderm 
differentiation and exit from pluripotency. The 
mode of action of these regulators appears to be 
specific for each mesoderm subtype depending on 
the regulation of T by pluripotency factors and 
FGF/ERK1/2 signaling (Fig. 5). These mechanisms 
represent an additional step to understand the 




      hESC culture and differentiation - H9 hESCs 
(WiCell, Madison, WI, USA) were cultured on 
vitronectin coated plates (10µg/ml, Stem Cell 
Technologies) in E6 media supplemented with 
2ng/ml TGF-β (R&D) and 25ng/ml FGF2 (Dr. 
Marko Hyvönen, Cambridge University). Cells 
were maintained by weekly passaging using 0.5mM 
EDTA (Thermo Fisher Scientific). CDK1 iKD H9 
hESCs cells were grown in the same conditions, 
supplemented with 1µg/ml puromycin for selection 
of antibiotic resistant cells. CDK1 knockdown was 
induced by adding 2µg/ml tetracycline 
hydrochloride (TET) (Sigma-Aldrich) to the culture 
medium 4 days prior to the start of differentiation.     
      The cells were differentiated into the three germ 
layers and functional cell types as previously 
described (20, 23). Mesoderm subtypes were 
generated in a 2-step protocol. For lateral plate 
mesoderm (LPM) formation, cells were cultured for 
36 hours in CDM-PVA supplemented with 20ng/ml 
FGF2, 10µM LY294002 (Promega) and 10ng/ml 
BMP4 (R&D). Subsequently cells were cultured for 
3 days in CDM-PVA supplemented with 20ng/ml 
FGF2 and 50ng/ml BMP4 changing medium every 
two days.  For cardiac mesoderm (CM) formation, 
cells were cultured for 36 hours in CDM-BSA 
(without insulin) supplemented with 20ng/ml 
FGF2, 10µM LY294002, 10ng/ml BMP4 and 
50ng/ml Activin A (Dr. Marko Hyvönen, 
Cambridge University). Subsequently cells were 
cultured for 4 days in CDM-BSA (without insulin) 
supplemented with 8ng/ml FGF2, 10ng/ml BMP4, 
1µM IWR1 (WNT signalling inhibitor; Tocris 
Bioscience) and 0.5µM Retinoic Acid (Sigma-
Aldrich), changing medium every two days. For 
presomitic mesoderm (PSM) formation, cells were 
cultured for 36 hours in CDM-BSA (without 
insulin) supplemented with 20ng/ml FGF2 and 
8µM CHIR99021 (WNT signalling activator; 
Tocris Bioscience). Subsequently cells were 
cultured for 4 days in CDM-BSA (with insulin) 
supplemented with 4ng/ml FGF2, 1µM Retinoic 
Acid, 0.1µM LDN193189 (BMP signalling 
inhibitor; Sigma-Aldrich) and 10µM SB431542 
(TGF-β signalling inhibitor; Tocris Bioscience). 
For mesoderm differentiation cells were plated on 
gelatin and mouse embryonic fibroblast (MEF) 
medium coated plates. Functional differentiation of 
the mesoderm subtypes was performed as described 
in the supplementary information.  
      RNA extraction, cDNA synthesis and RT-qPCR 
- Total RNA was extracted using the GenElute™ 
Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich) and the On-Column DNase I Digestion set 
(Sigma-Aldrich) according to the manufacturer’s 
instructions. RNA was reverse transcribed using 
250ng random primers (Promega), 0.5mM dNTPs 
(Promega), 20U RNAseOUT, 0.01M DTT and 25U 
of SuperScript II (all from Invitrogen).  The 
resulting cDNA was diluted 30-fold for the qPCR 
reaction. Quantitative PCR mixtures were prepared 
using the KAPA SYBR® FAST qPCR Master Mix 
(2X) Kit (Kapa Biosystems), 4.2µl of cDNA and 
200nM of each of the forward and reverse primers. 
Samples were run on 384 well plates using the 
QuantStudio 12K Flex Real-Time PCR System 
machine and results analysed using the delta-delta 
cycle threshold method (ΔΔCt). Expression values 
were normalized to the housekeeping gene 
Porphobilinogen Deaminase (PBGD). Primer 
sequences are listed in supplementary table 1. 
      Immunocytochemistry - Cells were fixed in 4% 
Paraformaldehyde (PFA) for 20 minutes at 4ºC 
followed by one wash with PBS. Cells were 
subsequently blocked and permeabilised at room 




temperature for 30 minutes in PBS with 4% donkey 
serum (Bio-Rad) and 0.1% Triton X-100 (Sigma-
Aldrich). Primary antibodies were diluted in the 
same buffer and incubated with the cells overnight 
at 4ºC. After three washes with PBS, cells were 
incubated with AlexaFluor secondary antibodies 
for 1 hour at room temperature protected from light. 
Cells were subsequently washed three times for 5 
minutes with PBS, adding Hoechst 33258 (bis-
Benzimide H, 1: 10,000 dilution; Sigma-Aldrich) 
during the first wash to stain nuclei. The antibodies 
used are listed in supplementary table 2. 
      Alcian blue staining - Monolayer cultures of 
chondrocytes were fixed in 4% paraformaldehyde 
(PFA) for 20 minutes at 4ºC. Cells were then 
washed with 0.5N HCl and stained overnight with 
0.25% (w/v) Alcian Blue 8GX (Sigma-Aldrich) in 
0.5N HCl. Stained cells were visualized using a 
Leica dissecting microscope. Alcian Blue dye was 
solubilized by overnight incubation with 8M 
guanidine hydrochloride (Sigma-Aldrich) and 
quantified by absorbance at 595nm using a 
spectrophotometer.  
      Generation of CDK1 inducible knockdown line 
– Knockdown for CDK1 was performed using the 
single optimised inducible knockdown method as 
previously described (24, 53). Multiple shRNAs for 
the CDK1 gene were obtained from the validated 
shRNA database at Sigma-Aldrich. Briefly, 
shRNAs were introduced in the psOPTiKD plasmid 
between the BglII and SalI-HF sites. The 
psOPTiKD-shCDK1 vector was targeted to the 
AAVS1 locus by using 6μg of each of the following 
vectors: psOPTiKD-shCDK1, pZFN.AAVS1-
KKR, and pZFN.AAVS1-ELD.  H9 hESCs were 
nucleofected using the Lonza P3 Primary Cell 4D-
Nucleofector X Kit and monoclonal colonies were 
selected for 7-10 days with 1 μg/ml of puromycin 
(Sigma-Aldrich). Tetracycline hydrochloride 
(Sigma-Aldrich) was used at 1μg/ml to induce the 
expression of the shRNA. Knockdown of CDK1 
was confirmed by Western blot using anti-CDK1 
antibody (Abcam, Ab133327). The shRNA 
sequences are listed in supplementary table 3.      
Cellular fractionation and Western blot - Cells 
were washed once with PBS and harvested with cell 
dissociation buffer (CDB; Gibco) for 10 minutes at 
37ºC. After one wash with cold 1% BSA-PBS, 
pellets were collected by centrifugation at 4ºC and 
300g for 3 minutes. For isolation of the cytoplasmic 
fraction, pellets were resuspended in 6 times packed 
cell volume equivalent of Isotonic Lysis Buffer 
(10mM Tris-HCl, 3mM CaCl, 2mM MgCl2, 0.32M 
sucrose, pH 7.5) supplement with protease and 
phosphatase inhibitors (Roche) and incubated for 
12 minutes on ice. 0.3% Triton X100 (Sigma-
Aldrich) was added for a further 3 minutes and 
samples were centrifuged at 1,800rpm for 5 minutes 
at 4ºC. The supernatant (cytoplasmic fraction) was 
collected in a fresh chilled tube. The nuclear pellet 
was washed once with Isotonic Lysis Buffer and 
centrifuged at 4,000rpm for 3 minutes at 4ºC. The 
nuclear pellet was resuspended in 2 times of the 
original packed cell volume equivalent of Nuclear 
Lysis Buffer (50mM Tris-HCl, pH 7.5, 100mM 
NaCl, 50mM KCl2, 1mM EDTA, 10% Glycerol, 
0.3% Triton X-100) supplemented with protease 
and phosphatase inhibitors (Roche), homogenized 
with a pellet pestle (Kimble Chase) and incubated 
for 30 minutes on ice. Subsequently, 125 units of 
benzonase nuclease (Sigma-Aldrich) was added to 
the lysates and incubated at room temperature for 
45 minutes to remove nucleic acids. For extraction 
of whole cell lysate cells were lysed with RIPA 
lysis buffer (50mM Tris-HCl, 150mM NaCl, 1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% 
SDS, pH 8.0). Protein was quantified using the 
Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific) according to the manufacturer’s 
instructions. Lysates were prepared for Western 
blot by adding 1x NuPAGE LDS Sample Buffer 
(Thermo Fisher Scientific) with 1% β-
mercaptoethanol and incubated at 95ºC for 5 
minutes. Lysates (10-35 µg of protein) were 
electrophoresed on 12% NuPAGE Bis-Tris Precast 
Gels (Thermo Fisher Scientific) with NuPAGE 
MOPS SDS Running Buffer (Thermo Fisher 
Scientific). For identification of the size of the 
target protein, Precision Plus Protein Ladder was 
used (Bio-Rad). Protein was transferred on PVDF 
membranes (Bio-Rad) by liquid transfer using 
NuPAGE Transfer Buffer (Thermo Fisher 
Scientific). Membranes were blocked using 4% 
non-fat dried milk in Tris-buffered saline and 0.1% 
Tween (TBST buffer) for 30 minutes and probed 
with primary antibody overnight at 4ºC in TBST. 
Following 3 washes of 5 minutes each with TBST, 
membranes were incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibody 
for 1 hour at room temperature in TBST. 
Membranes were then washed 3 times for 5 minutes 
with TBST and incubated with Pierce ECL Western 




Blotting Substrate and exposed to X-Ray Super RX 
Films (Fujifilm). In cases where Western blot 
membranes were incubated with more than one 
antibodies, the membranes were stripped using 
mild stripping buffer (1.5% Glycine, 0.1% SDS, 
1% Tween 20, pH 2.2). Membranes were incubated 
twice for 10 minutes with the stripping buffer, twice 
for 10 minutes with PBS, twice for 5 minutes with 
TBST prior to blocking and incubation with 
primary antibody. The antibodies used are listed in 
supplementary table 4. 
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FIGURE 1. Production of mesoderm subtypes from hPSCs. A, Schematic overview of the differentiation 
protocol. LPM was induced by FGF2, the PI3K inhibitor LY294002 and BMP4 and then SMCs were 
generated using TGFβ and PDGF-BB. CM was induced by Activin, FGF2, the PI3K inhibitor LY29400 
and BMP4 and cardiac cells were obtained by inhibiting WNT signaling in the presence of BMP4, FGF2 
and Retinoic Acid (RA). PSM was induced by FGF2 and the WNT signalling agonist CHIR99021. PSM 
was then generated using FGF2, RA and dual inhibition of TGFβ and BMP4 signalling using the small 
molecules SB431542 and LDN193189 respectively. Chondrocyte differentiation was induced by FGF2 and 
BMP4. B, RT-qPCR analysis for expression of pluripotency (NANOG) and mesoderm markers (T, NKX2.5, 
TAGLN and CNN1) during SMC differentiation. C, Immunostaining analysis for the expression of early 
mesoderm markers BRACHYURY, NKX2.5 and SMC marker TAGLN. Scale bar: 200µm. D, RT-qPCR 
analysis for the expression of pluripotency (NANOG) and mesoderm markers (EOMES, NKX2.5, TNNT2 
and ACTN1) during cardiomyocyte differentiation. E, Immunostaining analysis for the anterior primitive 
streak marker EOMES, CM marker NKX2.5 and cardiomyocyte marker Troponin T. Scale bar: 200µm. F, 
RT-qPCR analysis for expression of pluripotency (NANOG) and mesoderm (T, CDX2, COL2A1 and ACAN) 
markers during chondrogenic differentiation. G, Immunostaining analysis for the expression of early 
mesoderm marker BRACHYURY, PSM marker PAX3 and Alcian blue staining of chondrocytes 
differentiation. Scale bar: 200µm. Error bars represent ±SD (n=6).  Ordinary one-way ANOVA test 



















































































FIGURE 2. Inhibition of cell cycle regulators blocks induction of mesoderm subtypes. A, Schematic 
showing the action of the different cell cycle regulator inhibitors used in the study. B, Schematic overview 
of experimental setup to investigate the role of cell cycle regulators in mesoderm specification. For each 
experiment hESCs were differentiated in the absence (DMSO) or presence of inhibitor. C, RT-qPCR 
analysis for the expression of mesoderm markers (T and HAND1) during LPM induction. D, 
Immunostaining analysis for BRACHYURY expression during LPM induction. Scale bar: 200µm. E, RT-
qPCR analysis for the expression of mesoderm markers (T and EOMES) during CM induction. F, 
Immunostaining analysis for EOMES expression during CM induction. Scale bar: 200µm. G, RT-qPCR 
analysis for the expression of mesoderm markers (T and CDX2) during PSM induction. H, Immunostaining 
analysis for the expression of BRACHYURY during PSM induction. Scale bar: 200µm. Error bars represent 
±SD of 4 independent experiments. Unpaired t-test was performed. Differences between DMSO and 




























FIGURE 3. BMP, WNT and FGF signaling pathways are not affected by inhibition of G1 regulators. 
A, schematic overview of experimental setup to determine activity of BMP, WNT and FGF signaling upon 
treatment with G1 phase regulator inhibitors. B-C, Western blot and densitometry analyses for phospho-
SMAD1/5 and total SMAD1 to determine activity of BMP signaling in DMSO-treated vs cells treated with 
G1 regulator inhibitors during LPM (B) and CM induction (C). D, Western blot and densitometry analyses 
for phospho-β-catenin and total β-catenin to determine activity of WNT signaling. E, Western blot and 
densitometry analyses for phospho-ERK1/2 and total ERK1/2 to determine activity of FGF signaling. Blot 
represents samples run on the same gel. Α-tubulin and Histone H3 were used as loading controls for the 
cytoplasm and the nuclear fractions respectively. 
 































FIGURE 4. Inhibition of CDK1 decreases BMP and FGF signaling pathway activity. A-B, Western 
blot and densitometry analyses for phospho-SMAD1/5 and total SMAD1 to determine activity of BMP 
signaling in DMSO-treated vs cells treated with the CDK1 inhibitor RO-3306 during LPM (A) and CM 
induction (B). C, Western blot and densitometry analyses for phospho-β-catenin and total β-catenin to 
determine activity of WNT signalling in DMSO-treated vs cells treated with the CDK1 inhibitor RO-3306 
during PSM induction. D-G, Western blot and densitometry analyses for phospho-ERK1/2 and total 




ERK1/2 to determine activity of FGF signaling in pluripotency conditions (D) and during LPM (E), CM 
(F) and PSM induction (G). Α-tubulin and Histone H3 were used as loading controls for the cytoplasm and 
the nuclear fractions respectively. H, Western blot analysis of CDK1 iKD cells. Pluripotent cells were 
treated with tetracycline for 4 days prior to induction of differentiation. Following 36 hours of mesoderm 
subtype differentiation, cells were harvested for analysis of phospho-ERK1/2 and CDK1 expression. 
Graphs show densitometric analysis of protein relative to loading control α-tubulin and normalised to –TET 
treatments. I-K, RT-qPCR analysis for expression of differentiation and pluripotency markers during 
induction of LPM (I), CM (J) and PSM (K). Error bars represent ±SD (n=6). Ordinary one-way ANOVA 
test followed by Tukey’s test for multiple comparisons was performed. Differences between DMSO and 









































FIGURE 5. Model depicting the role of CDK1 in mesoderm specification.  Schematic of main findings 
on role of CDK1 in mesoderm patterning. CDK1 regulates FGF/ERK1/2 signaling to control BRACHYURY 
expression and subsequent mesoderm differentiation. Additionally, CDK1 could be directly or indirectly 
regulating expression of OCT4/NANOG to drive LPM formation.  
 
